Form 4: KALA BIO Officer Sells Shares to Cover Tax Obligations

Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA BIO, Inc., sold 5,251 shares of common stock for tax withholding purposes.

Summary

• Romulus K. Brazzell, KALA BIO's Head of Research and Development and Chief Medical Officer, sold 5,251 shares of the company's common stock.
• The transaction occurred on June 24, 2025, at a weighted average price of $4.01 per share, with individual sales ranging from $3.87 to $4.12.
• This sale was executed under a pre-arranged 10b5-1 trading plan, which was adopted on November 9, 2020.
• The primary purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) that were granted on June 22, 2023.
• Following this transaction, Mr. Brazzell beneficially owns 82,698 shares of KALA BIO common stock, which includes 35,952 unvested RSUs.

Sentiment

Score: 5

Explanation: The transaction is a routine sale by an officer to cover tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan, which is a common and generally neutral event and does not indicate a change in company fundamentals or management's confidence.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This transaction represents a routine insider stock sale, common across all industries, where executives manage their equity compensation, often through pre-arranged trading plans to cover tax liabilities upon vesting of restricted stock units.

Stakeholder Impact

• Minimal direct impact on shareholders as it is a routine, pre-planned sale for tax purposes, not indicative of a change in company fundamentals or management's confidence.

Key Dates

Keywords

KALA BIO, KALA, Romulus K. Brazzell, SEC Form 4, insider trading, stock sale, 10b5-1 plan, restricted stock units, RSU, tax withholding, officer transaction